It is important to understand the differences between risk-based decision making and other decision making in a pharmaceutical quality system.

While this approval addresses breast cancer, olaparib in combination with durvalumab was approved by the EU in August 2024 for treatment of endometrial cancer.

Brian Feth, Jonathan Grinstein, PhD, Beth Willers, and Laks Pernenkil go behind the headlines to discuss major news announcements made during the JP Morgan Healthcare Conference, a wave of new ...

The platform is live with full functionality for use by marketing authorization holders and national competent authorities to report drug supply information.

The deal is being made for an all-cash price of $250 million, but with an additional $752.5 million available in potential milestone payments. The transaction adds a pipeline of early-stage drug ...

In this exclusive Drug Digest video interview Anil Kane from Thermo Fisher Scientific will be tackling the topic of advances in small-molecule manufacturing and several other experts will provide ...